ArticleBlood advances2026

Phase 1b study of ABBV-744, a novel, selective BET inhibitor, as monotherapy for patients with myelofibrosis.

John Mascarenhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.